ALLMedicine™ Parathyroid Hormone-related Peptide Center
Research & Reviews 175 results
https://doi.org/10.1016/S1470-2045(21)00133-9
The Lancet. Oncology; Braat AJAT, Heerma van Voss MR et. al.
May 1st, 2021 - 99mTc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancer.|2021|Braat AJAT,Heerma van Voss MR,Bijlsma RM,|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054046
BMJ Case Reports; Ferrel B, Franko J et. al.
Apr 16th, 2021 - An asymptomatic 68-year-old woman who presented with an isolated hypercalcaemia was diagnosed with a rare, previously unsuspected parathyroid hormone-related peptide (PTHrP)-producing pancreatic neuroendocrine tumour. She underwent an extensive op...
https://doi.org/10.1097/CAD.0000000000001051
Anti-cancer Drugs; Ponnapakkam T, Anbalagan M et. al.
Feb 17th, 2021 - Patients with advanced breast cancer often develop bone metastases. Treatment is limited to palliative care. Parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) antagonists for bone metastases failed clinically due to short half-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792014
BMC Endocrine Disorders; Brun VH, Knutsen E et. al.
Jan 8th, 2021 - Hypercalcemia of malignancy is relatively common in several cancers. However, in colorectal cancer, paraneoplastic phenomena that cause hypercalcemia is uncommon. In the few cases that are reported, secretion of parathyroid hormone-related peptide...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500469
The Journal of Clinical Endocrinology and Metabolism; Cosman F, Peterson LR et. al.
Jul 13th, 2020 - Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. We assessed the cardiovascular safety profile of abaloparatide. ...
Clinicaltrials.gov 177 results
https://doi.org/10.1016/S1470-2045(21)00133-9
The Lancet. Oncology; Braat AJAT, Heerma van Voss MR et. al.
May 1st, 2021 - 99mTc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancer.|2021|Braat AJAT,Heerma van Voss MR,Bijlsma RM,|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054046
BMJ Case Reports; Ferrel B, Franko J et. al.
Apr 16th, 2021 - An asymptomatic 68-year-old woman who presented with an isolated hypercalcaemia was diagnosed with a rare, previously unsuspected parathyroid hormone-related peptide (PTHrP)-producing pancreatic neuroendocrine tumour. She underwent an extensive op...
https://doi.org/10.1097/CAD.0000000000001051
Anti-cancer Drugs; Ponnapakkam T, Anbalagan M et. al.
Feb 17th, 2021 - Patients with advanced breast cancer often develop bone metastases. Treatment is limited to palliative care. Parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) antagonists for bone metastases failed clinically due to short half-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792014
BMC Endocrine Disorders; Brun VH, Knutsen E et. al.
Jan 8th, 2021 - Hypercalcemia of malignancy is relatively common in several cancers. However, in colorectal cancer, paraneoplastic phenomena that cause hypercalcemia is uncommon. In the few cases that are reported, secretion of parathyroid hormone-related peptide...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500469
The Journal of Clinical Endocrinology and Metabolism; Cosman F, Peterson LR et. al.
Jul 13th, 2020 - Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. We assessed the cardiovascular safety profile of abaloparatide. ...
News 1 results
https://www.medscape.com/viewarticle/938943
Abstract and Introduction Abstract Context: Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. Objectives: We asses...
